Teclistamab results in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory myeloma

 Researchers at the Memorial Sloan Kettering Cancer Center in New York recently released findings of a phase I/II study of patients with relapsed or refractory multiple myeloma who received a "once-weekly subcutaneous dose of a bispecific antibody, teclistamab that mediates T-cell activation and subsequent lysis of myeloma cells expressing B-cell maturation antigen (BCMA)."  Of the 165 patients who were administered teclistamab, 65 patients (39.4%) had a complete response or better after a follow-up period of 14.1 months.

To read more about this study, click here.   

Sources mentioned:  Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med 2022;387:495-505.

Mailankody S, Landgren O. T-Cell Engagers — Modern Immune-Based Therapies for Multiple Myeloma. N Engl J Med 2022;387:558-561.